• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

    4/30/25 8:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email

    – Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed –

    LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, has partnered with Country Music Association, Academy of Country Music, and GRAMMY Award-winning country star, Carly Pearce, to share her personal experience with recurrent pericarditis and encourage self-advocacy through Kiniksa's Life DisRPted campaign. Pearce announced that she was diagnosed with recurrent pericarditis while on tour in 2024, after experiencing multiple flares over the previous four years.

    "It wasn't until my fourth recurrent pericarditis flare — after seeing many doctors and receiving various diagnoses — that I was finally accurately diagnosed with recurrent pericarditis. During this time, it wasn't only the symptoms that took a toll on me, but also the fear of the next flare. I remember thinking, ‘I'm afraid to get on the airplane,' and ‘I'm afraid to get on the stage, because what if it happens again?'" said Pearce, Grand Ole Opry and Kentucky Music Hall of Fame member. "My hope is that through my work on the Life DisRPted campaign, I inspire others to advocate for themselves, share their symptoms, and not wait to talk to their doctors."

    "Greater awareness is the first step to earlier diagnosis and intervention, which is critical for protecting patients from unnecessary suffering and future recurrent pericarditis flares," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. "Carly understands the physical and emotional toll of this disease firsthand, and we are honored to help her share her powerful story. By providing information on recognizing symptoms, understanding the disease, and accessing appropriate care, our goal is to empower patients with the tools to take control back from recurrent pericarditis."

    Patients experiencing recurrent pericarditis flares, characterized by chest pain but often also tiredness, shortness of breath, or inability to exercise as much as normal, suffer wide-ranging effects on quality of life, physical activity, and overall well-being. Recurrent pericarditis can be challenging to diagnose since many different conditions can cause similar symptoms, and recurrent pericarditis may not be the obvious diagnosis.

    First launched in October 2024 featuring Henrik Lundqvist, former National Hockey League goaltender and Hockey Hall-of-Fame inductee, Life DisRPted is a national campaign focused on raising awareness of recurrent pericarditis, its impact on quality of life, and the critical importance of early diagnosis. Through Life DisRPted, Pearce is sharing her personal journey with recurrent pericarditis in a video titled "The Power of Knowing," helping to shed light on the realities of living with the disease and the importance of self-advocacy. The video is available on LifeDisRPted.com, which also features a downloadable Doctor Discussion Guide to help patients prepare for conversations with their healthcare providers.

    To hear Carly Pearce's story, visit LifeDisRPtedCarly.com

    About Recurrent Pericarditis

    Recurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids.

    About Kiniksa

    Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa's portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

    About Carly Pearce

    Fiercely rooted in the classics, GRAMMY Award-winning singer-songwriter Carly Pearce lit a fire with her debut album Every Little Thing and the PLATINUM-certified history-making title track, and she hasn't slowed down since. With the praised release of her highly anticipated fourth album, hummingbird (June 7, Big Machine Records), Pearce continues to resonate with her honest lyrics and timeless musicality. The critically acclaimed album includes the blazing "truck on fire" as well as lead single "we don't fight anymore" (featuring Chris Stapleton) which earned Pearce her second GRAMMY nomination for Best Country Duo/Group Performance and fifth Top 5 Country Radio hit. On March 14th, Pearce released hummingbird: no rain, no flowers, a deluxe edition of the album with five new tracks and is currently performing the new music on her headlining hummingbird world tour. Previously, her critically acclaimed and commercially lauded third studio album 29 produced Country Radio chart toppers including "Never Wanted to Be That Girl" with Ashley McBryde which gave Pearce her second consecutive ACM Music Event of the Year in 2022 and marked the third duet between two solo women to top Billboard's Country Airplay chart. The song also took home the 2022 CMA Musical Event of the Year and won a GRAMMY Award for Best Country Duo/Group Performance, marking Pearce's first, and making history as the first female pairing to win in the category. In addition, Pearce's 3x PLATINUM-certified "I Hope You're Happy Now" with Lee Brice won both the 2020 CMA Awards Musical Event and 2021 ACM Awards Music Event, plus ACM Single of the Year. Both a Grand Ole Opry and Kentucky Music Hall of Fame member, Pearce recently made her 100th performance at the Grand Ole Opry. For more information, visit CarlyPearce.com.

    Every Second Counts! ®

    Kiniksa Investor Contact

    Jonathan Kirshenbaum

    (781) 829-3949

    [email protected]

    Kiniksa Media Contact

    Tyler Gagnon

    (781) 431-9100

    [email protected]

    Carly Pearce Media Contacts

    Erica Gerard

    [email protected]

    Avery Robinson

    [email protected]

    A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6d3f6284-9736-4ce2-91e2-2c3934f93925



    Primary Logo

    Get the next $KNSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

      – Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed – LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, has partnered with Country Music Association, Academy of Country Music, and GRAMMY Award-winning country star, Carly Pearce, to share her personal experience with recurrent

      4/30/25 8:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF COMMERCIAL OFFICER Moat Ross exercised 10,122 units of Class A Ordinary Share at a strike of $17.76 and sold $283,416 worth of Class A Ordinary Share (10,122 units at $28.00) (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:54:51 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Tessari Eben

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:53:14 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Megna Michael R

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:52:19 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:32:31 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:15:22 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/13/24 4:30:25 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    SEC Filings

    See more
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      5/7/25 5:13:12 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      5/7/25 4:00:34 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

      10-Q - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

      4/29/25 4:15:30 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      3/13/25 7:43:42 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      9/13/24 7:34:05 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $34.00

      5/3/24 11:21:30 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Financials

    Live finance-specific insights

    See more
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren's Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and c

      2/25/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care